Press Releases

Press Releases

Date	Title	Format
September 1, 2022	Chinook Therapeutics to Present at Upcoming Investor Conferences	PDF Version
August 8, 2022	Chinook Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results	PDF Version
August 4, 2022	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	PDF Version
August 2, 2022	Chinook Therapeutics to Present at Upcoming Investor Conferences	PDF Version
July 5, 2022	Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2022	PDF Version
July 5, 2022	Chinook Therapeutics Receives Orphan Drug Designation from European Commission for BION-1301 for Treatment of Primary IgA Nephropathy (IgAN)	PDF Version
May 24, 2022	Chinook Therapeutics Announces Pricing of a $105 Million Public Offering	PDF Version
May 24, 2022	Chinook Therapeutics Announces Proposed Public Offering	PDF Version
May 20, 2022	Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022	PDF Version
May 19, 2022	Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022	PDF Version

Email Alerts

Investors